Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Nov 11:11:78.
doi: 10.1186/1742-4755-11-78.

Patients' administration preferences: progesterone vaginal insert (Endometrin®) compared to intramuscular progesterone for Luteal phase support

Angeline N Beltsos  1 , Mark D Sanchez  2 , Kevin J Doody  3 , Mark R Bush  4 , Alice D Domar  5 , Michael G Collins  6
Affiliations
Clinical Trial

Patients' administration preferences: progesterone vaginal insert (Endometrin®) compared to intramuscular progesterone for Luteal phase support

Angeline N Beltsos et al. Reprod Health. .

Abstract

Background: Administration of exogenous progesterone for luteal phase support has become a standard of practice. Intramuscular (IM) injections of progesterone in oil (PIO) and vaginal administration of progesterone are the primary routes of administration. This report describes the administration preferences expressed by women with infertility that were given progesterone vaginal insert (PVI) or progesterone in oil injections (PIO) for luteal phase support during fresh IVF cycles.

Methods: A questionnaire to assess the tolerability, convenience, and ease of administration of PVI and PIO given for luteal phase support was completed by infertile women diagnosed with PCOS and planning to undergo IVF. The women participated in an open-label study of highly purified human menopausal gonadotropins (HP-hMG) compared with recombinant FSH (rFSH) given for stimulation of ovulation.

Results: Most women commented on the convenience and ease of administration of PVI, while a majority of women who administered IM PIO described experiencing pain. In addition, their partners often indicated that they had experienced at least some anxiety regarding the administration of PIO. The most distinguishing difference between PVI and PIO in this study was the overall patient preference for PVI. Despite the need to administer PVI either twice a day or three times a day, 82.6% of the patients in the PVI group found it "very" or "somewhat convenient" compared with 44.9% of women in the PIO group.

Conclusions: The results of this comprehensive, prospective patient survey, along with findings from other similar reports, suggest that PVI provides an easy-to-use and convenient method for providing the necessary luteal phase support for IVF cycles without the pain and inconvenience of daily IM PIO. Moreover, ongoing pregnancy rates with the well-tolerated PVI were as good as the pregnancy rates with PIO.

Trial registration: ClinicalTrial.gov, NCT00805935.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Convenience, ease, and overall patient satisfaction of administering/dosing progesterone vaginal insert (PVI) and progesterone in oil (PIO).
See this image and copyright information in PMC

References

    1. Check JH. Luteal phase support in assisted reproductive technology treatment: Focus on endometrin(r) (progesterone) vaginal insert. Ther Clin Risk Manag. 2009;5:403–407. doi: 10.2147/TCRM.S4192. - DOI - PMC - PubMed
    1. DiLuigi AJ, Nulsen JC. Effects of gonadotropin-releasing hormone agonists and antagonists on luteal function. Curr Opin in Obstet ynecol. 2007;19:258–265. doi: 10.1097/GCO.0b013e3281338874. - DOI - PubMed
    1. ASRM Practice Bulletin Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. Fertil Steril. 2008;89:789–792. doi: 10.1016/j.fertnstert.2008.02.012. - DOI - PubMed
    1. Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P. An update of luteal phase support in stimulated IVF cycles. Hum Reprod Update. 2007;13:581–590. doi: 10.1093/humupd/dmm021. - DOI - PubMed
    1. Penzias AS, Alper MM. Luteal support with vaginal micronized progesterone gel in assisted reproduction. Reprod Biomed Online. 2003;6:287–295. doi: 10.1016/S1472-6483(10)61847-0. - DOI - PubMed

Publication types

MeSH terms

Associated data